СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ У БОЛЬНЫХ С САХАРНЫМ ДИАБЕТОМ
Ключевые слова:
Сахарный диабет, сердечная недостаточность, антигипергликемические препаратыАннотация
Пациенты с сахарным диабетом (СД) имеют более чем в 2 раза больший риск развития сердечной недостаточности (СН; СН со сниженнойфракцией выброса и СН с сохраненной фракцией выброса). Сердечно-сосудистые исходы, госпитализация и прогноз у пациентов с сахарным диабетом хуже, чем у пациентов без него. Помимо структурных и функциональных изменений, характерных для диабетической кардиомиопатии, в их основе лежит сложный патофизиологический механизм. Несмотря на успех многих широко используемых антигипергликемических препаратов при СД 2 типа, высокая распространенность СН сохраняется. Таким образом, это повышает вероятность того, что дополнительные факторы, помимо гликемии, могут способствовать повышению риска СН при СД. В этом обзоре обобщен уровень знаний о влиянии существующих антигипергликемических препаратов на СН и обсуждаются потенциальные механизмы положительных или отрицательных эффектов.
Библиографические ссылки
Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations //Cardiovasc Hematol Agents Med Chem.-2012.- N10.- P.124–134
Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes //J Am Coll Cardiol. – 2009 - Vol.54. - Vol.422–428
Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure //Circ Heart Fail. – 2011. - Vol.4. – P.53–58
Ahren B. DPP-4 inhibitors //Best Pract Res Clin Endocrinol Metab. – 2007. - Vol.21. – P.517–533
American Diabetes Association. Standards of medical care in diabetes–2014 //Diabetes Care. – 2014. – Vol.37(suppl 1). - S14–S80
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018 //Diabetes Care. – 2018. - Vol.41:S73–S85
Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk ofedema: a meta-analysis //Diabetes Res Clin Pract. – 2007. - Vol.76. – P.279–289
Bertrand L, Ginion A, Beauloye C, Hebert AD, Guigas B, Hue L, Vanoverschelde JL. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B //Am J Physiol Heart Circ Physiol. – 2006. – Vol.291. – H239–H250
Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment //Trends Endocrinol Metab. – 2012. - Vol.23. – P.205–215
Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis //Am Heart J. -2011. - Vol.162. – P.938.e2–948e2
Cheung N, Bluemke DA, Klein R, Sharrett AR, Islam FM, Cotch MF, Klein BE, Criqui MH, Wong TY. Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis //J Am Coll Cardiol. – 2007. - Vol.50. – P. 48–55
Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure //JACC Heart Fail. - 2015. - Vol.3. – P.136–145
Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study //Circulation. – 2000. - Vol.101. – P.2271–2276
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive //Drug Saf. – 2009. - Vol.32. – P.187–202
Duckworth W, Abraira C, Moritz T. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes //N Engl J Med. – 2009. - Vol.360. – P.129–139
Echouffo-Tcheugui JB, Masoudi FA, Bao H, Spatz ES, Fonarow GC. Diabetes mellitus and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure //Circ Arrhythm Electrophysiol. – 2016. - N9. - e004132
Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Heidenreich PA, Fonarow GC. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry //Am Heart J. – 2016. - Vol.182. – P.9–20
Erqou S, Lee CT, Suffoletto M, Echouffo-Tcheugui JB, de Boer RA, van Melle JP, Adler AI. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis //Eur J Heart Fail. - 2013 - Vol.15. – P.185–193
Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review //BMJ. – 2007. - Vol.335.- P.497
Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients //Circ Heart Fail. – 2013. - Vol.6. – P.395–402
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes //N Engl J Med. – 2008. - Vol.358. – P.2545–2559
Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia //N Engl J Med. – 2012. - Vol.367. – P.319–328
Gerstein HC, Jung H, Ryden L, Diaz R, Gilbert RE, Yusuf S; ORIGIN Investigators. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (Outcome Reduction With Initial Glargine Intervention) //Circulation.-2018. - Vol.137. - P.88–90
Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption //Nat Med. – 2005. - Vol.11. – P.861–866
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035 //Diabetes Res Clin Pract. – 2014. - Vol.103. – P.137–149
Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care //BMJ. – 2016. - Vol.354. – P.i3477
Hong J, Zhang Y, Lai S. SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease //Diabetes Care. – 2013. - Vol.36. – P.1304–1311
Horman S, Beauloye C, Vanoverschelde JL, Bertrand L. AMP-activated protein kinase in the control of cardiac metabolism and remodeling //Curr Heart Fail Rep. – 2012. - Vol.9. – P.164–173
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) //Diabetologia. – 2012. - Vol.55. – P.1577–1596
Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes //Int J Clin Pract. – 2008. - Vol.62. – P.1279–1284
Kaplan A, Abidi E, El-Yazbi A, Eid A, Booz GW, Zouein FA. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects //Heart Fail Rev. – 2018. - Vol.23. – P.419–437
Kernan WN, Viscoli CM, Furie KL. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack //N Engl J Med. – 2016. - Vol.374. – P.1321–1331
Lee M, Gardin JM, Lynch JC, Smith VE, Tracy RP, Savage PJ, Szklo M, Ward BJ. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the Cardiovascular Health Study //Am Heart J. – 1997. - Vol.133. – P.36–43
Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis //Stroke. – 2017. - Vol.48. – P.388–393
Li L, Li S, Liu J. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies //BMC Cardiovasc Disord. – 2016. -N16. – P.91
Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women //Diabetes Care. – 2014. - Vol.37. – P.3106–3113
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial //JAMA. – 2016. - Vol.316. – P.500–508
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes //N Engl J Med. – 2016. - Vol.375. – P.311–322
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes //N Engl J Med. -2017. - Vol.377. – P.723–732
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes //N Engl J Med. – 2017. - Vol.377. – P.644–657
Nolan CJ, Ruderman NB, Prentki M. Intensive insulin for type 2 diabetes: the risk of causing harm //Lancet Diabetes Endocrinol. – 2013. - N1. – P.9–10
Patel A, MacMahon S, Chalmers J. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes //N Engl J Med. -2008. - Vol.358. – P.2560–2572
Rados DV, Pinto LC, Remonti LR, Leitao CB, Gross JL. Correction: the association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials //PLoS Med. – 2016. - N13.–e1002091.
Riehle C, Abel ED. Insulin signaling and heart failure //Circ Res. – 2016. - Vol.118. – P.1151–1169
Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study //Ann Intern Med. – 2012. – Vol.157. – P.601–610
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis //Am J Cardiol. – 1972. - Vol.30. – P.595–602.
Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors //Circ Res. – 2018. - Vol.122. – P.1439–1459
Scirica BM, Bhatt DL, Braunwald E. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus //N Engl J Med. – 2013. - Vol.369. – P.1317–1326
Selvin E, Lazo M, Chen Y, Shen L, Rubin J, McEvoy JW, Hoogeveen RC, Sharrett AR, Ballantyne CM, Coresh J. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage //Circulation. – 2014. - Vol.130. – P.1374–1382
Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA, Wilde N, Pereira RO, Litwin SE, Berger JP, Abel ED. Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling //Endocrinology. – 2007. - Vol.148. – P.6047–6053
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagonlike peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure //J Card Fail. – 2006. - Vol.12. – P.694–699
Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice //J Clin Invest. – 2007. - Vol.117. – P.2791–2801
UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group //Lancet. – 1998. - Vol.352. – P.837–853
van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus //Circulation. – 2009. - Vol.119. – P.2069–2077
Wilding JP, Norwood P, T’joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin- independent treatment //Diabetes Care. -2009. - Vol.32. – P.1656–1662
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes //N Engl J Med.- 2015. - Vol.373. – P.2117–2128
2.Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies //Nat Rev Endocrinol. – 2016. - Vol.12. – P.616–622
